These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 11933951)
1. Changes to reporting of serious adverse events. Maloney DM Hum Res Rep; 2001 Mar; 16(3):5. PubMed ID: 11933951 [No Abstract] [Full Text] [Related]
2. Confidentiality certificates and privacy of research subjects. Maloney DM Hum Res Rep; 2002 May; 17(5):3. PubMed ID: 12708410 [No Abstract] [Full Text] [Related]
3. NIH panel to limit secrecy on gene therapy. Wadman M Nature; 1999 Nov; 402(6757):6. PubMed ID: 10573406 [No Abstract] [Full Text] [Related]
4. Making clinical trials safer for human subjects. Baram M Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112 [No Abstract] [Full Text] [Related]
5. The certificate of confidentiality application: a view from the NIH Institutes. Wolf LE; Zandecki J; Lo B IRB; 2004; 26(1):14-8. PubMed ID: 15281213 [No Abstract] [Full Text] [Related]
6. Regulating human gene therapy: legislative overreaction to human subject protection failures. Leavitt WJ Adm Law Rev; 2001; 53(1):315-41. PubMed ID: 16189905 [No Abstract] [Full Text] [Related]
7. Regulation of research with children: the evolution from exclusion to inclusion. Alexander D J Health Care Law Policy; 2002; 6(1):1-13. PubMed ID: 15017949 [No Abstract] [Full Text] [Related]
8. United States regulatory requirements for research involving human subjects. J Biolaw Bus; 1998; 1(2):39-53. PubMed ID: 12739542 [No Abstract] [Full Text] [Related]
9. The increasing opacity of gene therapy. Nature; 1999 Nov; 402(6758):107. PubMed ID: 10646989 [No Abstract] [Full Text] [Related]
10. IRBs, human subjects, and reporting adverse events. Maloney DM Hum Res Rep; 2005 Nov; 20(11):3. PubMed ID: 16358480 [No Abstract] [Full Text] [Related]
11. Is self-regulation enough today?: Evaluating the recombinant DNA controversy. Weiner C Health Matrix Clevel; 1999; 9(2):289-302. PubMed ID: 10787474 [No Abstract] [Full Text] [Related]
12. Practicing safer research: using the law to protect the confidentiality of sensitive research data. Wolf LE; Lo B IRB; 1999; 21(5):4-7. PubMed ID: 12625348 [No Abstract] [Full Text] [Related]
13. The new RAC: restructuring of the National Institutes of Health recombinant DNA Advisory Committee. Beach JE Food Drug Law J; 1999; 54(1):49-53. PubMed ID: 11758560 [No Abstract] [Full Text] [Related]
14. Policy statement of the American Society of Gene Therapy on reporting of patient adverse events in gene therapy trials. Woo SL Mol Ther; 2000 Jan; 1(1):7-8. PubMed ID: 10933905 [No Abstract] [Full Text] [Related]
15. Agencies said to be slow on research protections reform. Maloney DM Hum Res Rep; 2001 Jul; 16(7):3. PubMed ID: 11933954 [No Abstract] [Full Text] [Related]
16. IRBs, data sharing, and privacy of human subjects. Maloney DM Hum Res Rep; 2002 Apr; 17(4):3. PubMed ID: 12374179 [No Abstract] [Full Text] [Related]
17. Protecting vulnerable research subjects: practical realities of institutional review board review and approval. Wichman A J Health Care Law Policy; 1998; 1(1):88-104. PubMed ID: 15573431 [No Abstract] [Full Text] [Related]
18. Subject's parents say federal protection office had inherent conflict of interest. Maloney DM Hum Res Rep; 2000 Aug; 15(8):5-6. PubMed ID: 12199291 [No Abstract] [Full Text] [Related]